News

Article

Neurotech Pharmaceuticals receives priority review of BLA for NT-501 for treatment of MacTel

Author(s):

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

(Image Credit: AdobeStock/BillionPhotos.com)

(Image Credit: AdobeStock/BillionPhotos.com)

Neurotech Pharmaceuticals Inc announced the FDA has determined that the Biologic License Application (BLA) for NT-501, an investigational encapsulated cell therapy for the treatment of idiopathic juxtafoveal macular telangiectasia (MacTel), is sufficiently complete to permit a substantive review.

According to a news release, the application has a prescription drug user fee act (PDUFA) goal date of December 17, 2024.1

“This is a significant achievement for Neurotech,” said Richard Small, CEO of Neurotech. “I would like to express my gratitude to our employees for reaching this important milestone.”

The company noted in the news release that NT-501, an ocular implant designed to deliver sustained therapeutic doses of ciliary neurotrophic factor (CNTF) directly to the retina to slow the progression of the disease, leverages its Encapsulated Cell Therapy (ECT) platform to deliver CNTF for the treatment of chronic retinal diseases, such as MacTel.

CNTF is a potent neuroprotective protein that promotes the survival and maintenance of photoreceptors. This targeted therapy provides sustained delivery of CNTF, aiming to slow retinal degeneration and potentially improve long-term visual outcomes for patients.1

MacTel is a progressive, neurodegenerative disease of the retina that results in the deterioration of central vision, significantly impacting patients' quality of life.

Reference:
  1. Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (Revakinagene Taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel).; 2024. Accessed June 20, 2024. https://www.neurotechpharmaceuticals.com/wp-content/uploads/Neurotech_Press-Release_BLA_FINAL.pdf

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.